Alterity Therapeutics Ltd. (PRNAF) Financial Metrics & Key Ratios
💡 AI Analyst Insight
The current ratio below 1.0x warrants monitoring of short-term liquidity.
PRNAF Profit Margin, ROE & Profitability Analysis
PRNAF vs Healthcare Sector: How Alterity Therapeutics Ltd. Compares
How Alterity Therapeutics Ltd. compares to Healthcare sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
Is Alterity Therapeutics Ltd. Stock Overvalued? PRNAF Valuation Analysis 2026
Based on fundamental analysis, Alterity Therapeutics Ltd. has mixed fundamental signals relative to the Healthcare sector in 2026.
Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.
Alterity Therapeutics Ltd. Balance Sheet: PRNAF Debt, Cash & Liquidity
PRNAF Revenue Growth, EPS Growth & YoY Performance
PRNAF SEC Filings: Latest 10-K & 10-Q Analysis
Access official SEC EDGAR filings for Alterity Therapeutics Ltd. (CIK: 0001131343)
📋 Recent SEC Filings
❓ Frequently Asked Questions about PRNAF
What is the AI rating for PRNAF?
Alterity Therapeutics Ltd. (PRNAF) has an AI grade of N/A with 0% confidence, based on fundamental analysis of SEC EDGAR filings.
What are PRNAF's key strengths?
Claude: Analysis in progress.
What are the risks of investing in PRNAF?
Claude: Analysis in progress.
What is PRNAF's revenue and growth?
Alterity Therapeutics Ltd. reported revenue of N/A.
Does PRNAF pay dividends?
Alterity Therapeutics Ltd. does not currently pay dividends.
Where can I find PRNAF SEC filings?
Official SEC filings for Alterity Therapeutics Ltd. (CIK: 0001131343) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is PRNAF's EPS?
Alterity Therapeutics Ltd. has a diluted EPS of $0.00.
How is the AI analysis conducted?
Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined grade reflects both perspectives for balanced insights.
What is PRNAF's fundamental grade?
Based on our AI fundamental analysis in May 2026, Alterity Therapeutics Ltd. has a N/A grade with 0% confidence. Review the strengths and risks sections above for full context. This is not investment advice.
Is PRNAF stock overvalued or undervalued?
Valuation metrics for PRNAF: ROE of N/A (sector avg: 15%), net margin of N/A (sector avg: 12%). Compare these metrics with sector averages to assess valuation.
What is PRNAF's AI grade for 2026?
Our dual AI analysis gives Alterity Therapeutics Ltd. a combined N/A grade for 2026. Revenue is data pending, with profitability at or below sector average. Always conduct your own research.
What is PRNAF's free cash flow?
Alterity Therapeutics Ltd.'s operating cash flow is N/A, with capital expenditures of N/A.
How does PRNAF compare to other Healthcare stocks?
Vs Healthcare sector averages: Net margin N/A (avg: 12%), ROE N/A (avg: 15%), current ratio N/A (avg: 2).